"rationale","instanceType","label","description","uuid:ID","name","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","","The main design for the study","2c769313-6a42-4f4b-9900-1a47fafbc9cf","Study Design 1","StudyDesign_1"
